JPMorgan Resumes Allergen (AGN) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
UBS Cuts Allergan (AGN) PT, Ests But Remains Above Consensus
April 7, 2016 8:41 AM EDTUBS analyst, Marc Goodman, cited Allergen (NYSE: AGN) as a standalone company as one of his favorites. He thinks management said all the right things regarding capital deployment, M&A aggressiveness, cost cutting, its commitment to a R&D-driven business model, and its preparedness for this contingency (i.e., a deal break).... More
Susquehanna Downgrades Allergen (AGN) to Neutral
April 7, 2016 7:30 AM EDTSusquehanna downgraded Allergen (NYSE: AGN) from Positive to Neutral.
For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.
Shares of Allergen closed at $244.74 yesterday.
... MoreAllergan (AGN) Affirms Termination of Pfizer (PFE) Merger; Affirms Strength as Standalone Company
April 6, 2016 6:47 AM EDTAllergan plc (NYSE: AGN) announced that its merger agreement with Pfizer (NYSE: PFE) has been terminated by mutual agreement, effective . In connection with the termination of the merger agreement, Pfizer has agreed to pay Allergan $150 million for reimbursement of expenses associated with the transaction.
Allergan reiterated its compelling standalone growth profile and strategy following the announced termination of the combination of the two companies. Allergan is positioned to drive strong, sustainable growth powered by leading franchises, new potential blockbuster product launches and unmatched pipeline.
"While we... More
Pfizer (PFE) Announces Termination of Merger Agreement with Allergan (AGN)
April 6, 2016 6:45 AM EDTPfizer Inc. (NYSE: PFE) announced that the merger agreement between Pfizer and Allergan plc (NYSE: AGN) has been terminated by mutual agreement of the companies. The decision was driven by the actions announced by the U.S. Department of Treasury on April 4, 2016, which the companies concluded qualified as an Adverse Tax Law Change... More
